It’s the wire. The U.S. presidential election is only a week away, and the polls show that Biden has an advantage over President Trump. Investors are preparing. John Stoltzfus, chief investment strategist at Oppenheimer, notes that stocks have been churned over the past week as investors rebalanced, rotated, and added additional exposure to value stocks “while others took profits in growth names that had previously well before next year’s potentially higher capital gains and other taxes were up, “in case the Democrats are ahead. Highlighting that the expectation Stoltzfus argues that this renewed appetite for an improved COVID-19 vaccine is behind expanding investor appetite for stocks, “makes value stocks more attractive”. Going forward, the strategist underscores the Federal Reserve’s efforts to “underscore the case for economic recovery and the resilience and potential of stock markets from here.” Although a “blue wave” is seen as a potential risk, Stoltzfus believes this result very unlikely, and continued split control should ease market concerns. Given Stoltzfus’ outlook, our attention turned to three stocks that Oppenheimer analysts believe could rise at least 70% in the coming year In the TipRanks database, we found that every company has a consensus rating of “Strong Buy” from the broader analyst community. Chromadex (CDXC) Chromadex Focuses on Improving How People Work Oppenheimer believes the time is now to board on October 6th, CDXC released the Erg Results of the Phase 2 study evaluating a nutritional protocol containing the nicotinamide riboside (NR) product along with the current standard of care in mild to moderate COVID-19 patients. It should be noted that the study included approximately 100 patients and was conducted in partnership with ScandiBio Therapeutics at a research hospital in Istanbul, Turkey. Based on the data, patients given the NR plus standard-of-care combination were able to reduce recovery time by 29% (6.6 days versus 9.3 days). These findings complement existing NR-related research, including 11 published clinical studies and others on-going. According to management, a phase 3 study will start soon. Oppenheimer, 5-star analyst Brian Nagel, said: “We have been recommending CDXC for some time as an extremely compelling, if speculative, investment game for specialty consumers. We interpret [the] News as further indication that ChromaDex is continuing its extensive and admirable urge to well understand the science behind NR and its product of the same name, TruNiagen. “Nagel believes the consumer audience will expand in the future. “We are increasingly optimistic that ChromaDex and its partners will continue to build a range of NR-related research and management is working to reinforce an effective marketing message that mass market demand for NR and TruNiagen will increase, creating significant financial and operational levels Levels of CDXC Unleashed To this end, Nagel rates CDXC as outperforming (i.e. buying) along with a price target of $ 9. Should the target be met, a twelve month profit of 90% could be imminent. (To see Nagel’s track record, click here.) It’s not often that all analysts agree on a stock. When this happens, take note of it. CDXC’s Strong Buy Consensus Rating is based on 3 unanimous purchases. The stock’s average target price of $ 7.67 indicates an upward movement of 61% from the current stock price of $ 4.70. (See CDXC stock analysis on TipRanks) Apellis Pharmaceuticals (APLS) Next, we have Apellis Pharmaceuticals, which is developing innovative therapies that target complement-mediated diseases. With a solid line-up for 2021, Oppenheimer opens the table for this name in healthcare. Recently, APLS released an update to its pipeline, including its C3 systemic inhibitor pegcetacoplan, which targets C3G / IC-MPGN and ALS. 5-star analyst Justin Kim, who treats APLS for Oppenheimer, suggests that C3G and IC-MPGN represent a significant opportunity for systemic C3 inhibition based on data supporting the role of complement activation and deposition. Even with the “suboptimum” response ”from a leading factor D inhibitor, the analyst is optimistic about the C3 approach,“ which could show stronger and broader inhibition of the cascade. “It should be noted that an open phase 2 study with up to 12 patients was recently initiated. Given that Alexion’s C5 approach is being investigated in an ongoing Phase 3 ALS program, Kim has high hopes for this indication. “With ~ 200 patients enrolled in the Phase 2 APLS trial, the Company believes the trial could allow registration. With a potential case rate of ~ 5 / 100,000 in the US, ALS (and neurology) could represent the greatest longer-term opportunity for the C3 systemic pipeline, which is consistent with Alexion’s neurological focus, ”he said. If that weren’t enough, Pegcetacoplan is currently in phase 3 development for paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA). Although APLS faces fierce competition, Kim sees “a premium product profile in Pegcetacoplan based on the data available”. The analyst added, “With a potential PDUFA expected for PNH in mid-2021, we believe investors will continue to focus on potential commercial considerations for Pegcetacoplan’s lead indicator.” Referring to the GA opportunity, Kim stated, ” When we launched, we highlighted our appreciation for GA, which continues to be a potentially transformative catalyst for stocks when reading the study (Q3 2021). Now that the DERBY and OAKS studies have completed registration, we remain optimistic about Pegcetacoplan’s positioning in GA, the clinical power of the data currently available and the market opportunities. “With long-term fundamentals remaining robust and cheap, we continue to view APLS as an underrated biotech tracking for potential initial approval in a well-understood commercial rare disease market, significant optionality in the geographic atrophy of the blockbuster indication, and fascinating opportunities Early stage benefits (C3G, COVID-19, gene therapy). We expect management to continue to implement these goals and re-evaluate the shares, ”Kim concluded. Everything APLS was aiming for convinced Kim to keep its Outperform (i.e. Buy) rating. On top of the call, he left the target price at $ 62, suggesting upside potential of 71%. (To see Kim’s track record, click here.) What does the rest of the street have to say? There have been 4 purchases and 1 hold in the last three months. Therefore, APLS receives a strong buy consensus rating. Based on the average price target of $ 50.67, stocks could rise 47% over the next year. (See APLS stock analysis on TipRanks.) Boingo Wireless (WIFI) Boingo Wireless provides connectivity to mobile devices over small cell systems that span LTE and Wi-Fi spectrum and networks. According to Oppenheimer, the future of this company looks very promising. 5-star analyst Timothy Horan, who represents the company, explains to clients that uncertainties surrounding the pandemic and the rating made him downgrade the rating back in April. Now he sees an attractive entry point. Given that WIFI has solid assets in growing end markets (military and DAS) and the stock is trading at 13x Horan’s EBITDA in 2021, which is a 35% discount off a 20x purchase price and one Discount of 25% on trading with tower companies corresponds to an EBITDA of approx. 25x 2021E, the analyst believes an acquisition is likely. “We believe there is a high likelihood that Boingo will sell some or all of its business to Towers or an infrastructure-focused private equity firm in the next year. A strategic buyer could improve EBITDA by $ 15 million from unnecessary overheads alone. In addition, there is a strong appetite for wireless infrastructure, which is reflected in several recent transactions, ”said Horan. Most likely, the business will be split into three different companies, valued at around $ 800 million on a SoTP basis, compared to the current $ 500 million enterprise value according to Horan. He also argues that the Military / Multi-Family segment has an enterprise value business of $ 600 million based on an 18x EBITDA multiple and its EBITDA estimate of $ 34 million, with DAS and Wholesale another enterprise value of $ 34 million $ 200 million. Horan commented: “It is positive that more 4G / 5G frequencies are being made available and Boingo expects to go live with a carrier for the first phase of the LIRR by the end of 2020. The military business has proven its resilience through the pandemic. Boingo saw a sharp increase in traffic on military bases in the second quarter of 2020 and is expanding the higher ARPU 100Mbps service to more bases. Additionally, Horan expects WIFI’s third quarter results to be weak due to lower traffic at airports and venues, but expects revenue and cash EBITDA to have increased, most likely management has made significant efforts to address this reduce costs. “We believe Boingo’s wireless resources are unique, and the pandemic has highlighted the need for a critical neutral infrastructure to support connectivity. Recent acquisitions indicate strong interest in wireless infrastructure and Boingo’s valuation is attractive at current levels. The military and DAS were resilient and well positioned for the long term, ”concluded Horan. In keeping with his optimistic approach, Horan joined the bulls, upgraded the rating from Perform to Outperform and set a price target of $ 15. Investors could pocket a 63% gain if that goal is met in the next twelve months. (To see Horan’s track record, click here.) Do other analysts agree? You are. Only buy reviews have been given in the last three months, 7 to be exact. So the message is clear: WIFI is a strong buy. Given the average target price of $ 19.86, stocks could rise 116% over the next year. (See WIFI Stock Analysis on TipRanks.) To find great ideas for trading stocks at attractive valuations, visit TipRanks ‘Best Stocks to Buy, a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the analysts presented. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.